Akeso (OTCPK:AKES.F) - Stock Price, News & Analysis

AKES.F Stock Overview

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies.

AKES.F fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	4/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 45.2% below our estimate of its fair value

Earnings are forecast to grow 10.79% per year

Became profitable this year

Analysts in good agreement that stock price will rise by 22.3%

Risk Analysis

Shares are highly illiquid

Shareholders have been diluted in the past year

Akeso, Inc. Competitors

TG Therapeutics

NasdaqCM:TGTX

US$2.0b

POINT Biopharma Global

NasdaqCM:PNT

US$1.3b

Halozyme Therapeutics

NasdaqGS:HALO

US$4.9b

Kiniksa Pharmaceuticals

NasdaqGS:KNSA

US$1.3b

Price History & Performance

Summary of all time highs, changes and price drops for Akeso
Historical stock prices
Current Share Price	HK$6.32
52 Week High	HK$6.45
52 Week Low	HK$5.00
Beta	0.48
1 Month Change	-1.25%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	26.40%

Recent updates

Shareholder Returns

	AKES.F	US Biotechs	US Market
7D	0%	0.1%	2.2%
1Y	n/a	-1.0%	22.8%

Return vs Industry: Insufficient data to determine how AKES.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how AKES.F performed against the US Market.

Price Volatility

Is AKES.F's price volatile compared to industry and market?
AKES.F volatility
AKES.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.5%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Stable Share Price: AKES.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine AKES.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2012	2,778	Michelle Xia	www.akesobio.com

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors. It is also developing AK105, a PD-1 monoclonal antibody to treat classic Hodgkin’s lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, HNSCC, CRC, TNBC, and solid tumors/lymphoma; AK119, a CD73 monoclonal antibody for treating solid tumors and NSCLC; and AK109, a VEGFR-2 monoclonal antibody to treat GC, GEJ, NSCLC, HCC, and solid tumors.

Akeso, Inc. Fundamentals Summary

How do Akeso's earnings and revenue compare to its market cap?
AKES.F fundamental statistics
Market cap	US$5.39b
Earnings (TTM)	US$280.02m
Revenue (TTM)	US$624.87m

19.4x

P/E Ratio

8.7x

P/S Ratio

Is AKES.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AKES.F income statement (TTM)
Revenue	CN¥4.53b
Cost of Revenue	CN¥133.25m
Gross Profit	CN¥4.39b
Other Expenses	CN¥2.36b
Earnings	CN¥2.03b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	2.34
Gross Margin	97.06%
Net Profit Margin	44.81%
Debt/Equity Ratio	65.7%

How did AKES.F perform over the long term?

See historical performance and comparison

AKES.F Stock Overview

Rewards

Risk Analysis

Akeso, Inc. Competitors

NasdaqCM:TGTX

US$2.0b

NasdaqCM:PNT

US$1.3b

NasdaqGS:HALO

US$4.9b

NasdaqGS:KNSA

US$1.3b

Price History & Performance

Recent News & Updates

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC

Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

Recent updates

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC

Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

Akeso, Inc. Announces Innovative Clinical Development Roadmap

Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer

Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023

Akeso Publishes Results from Three Investigator-Initiated Trials

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

Akeso Announces Results of Phase Ib Clinical Trial for PD-1/VEGF Bispecific Antibody

Akeso Announces the Publication of the Phase 1a/1b First-In-Human Study

Akeso, Inc. Announces Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)

Akeso, Inc. Announces FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes

Akeso Inc. Announces Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-Line PD-L1 Positive Advanced NSCLC

Akeso, Inc. Announces the National Medical Products Administration Accepts the New Drug Application for the Ebdarokimab Injection (IL-12/IL-23 Monoclonal Antibody, AK101)

Akeso Inc. Announces First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-Line Treatment of Squamous NSCLC

Akeso, Inc. to Report First Half, 2023 Results on Aug 29, 2023

Akeso, Inc., Annual General Meeting, Jun 28, 2023

NMPA Accepts Akeso's Ebronucimab (PCSK9 ) Marketing Application in Two Cardiovascular Indications

Shareholder Returns

Price Volatility

About the Company

Akeso, Inc. Fundamentals Summary

19.4x

8.7x

Earnings & Revenue